Piceatannol Induces Mitochondrial Dysfunction in Toxoplasma gondii.

Area of Science:

• Parasitology
• Molecular Biology
• Pharmacology

Background:

• Toxoplasma gondii infections pose significant risks to immunocompromised individuals.
• Existing treatments for toxoplasmosis are limited by efficacy and toxicity.
• Novel therapeutic strategies are crucial for managing T. gondii infections.

Purpose of the Study:

• To investigate the anti-parasitic mechanisms of Piceatannol (PIC) against Toxoplasma gondii.
• To evaluate PIC's potential as a novel therapeutic agent for toxoplasmosis.
• To elucidate the molecular targets of PIC in T. gondii tachyzoites.

Main Methods:

• In vitro assessment of PIC's anti-parasitic activity and host cytotoxicity.
• Mitochondrial function assays, including membrane potential and ATP production measurements.
• Reactive oxygen species (ROS) level analysis.
• Transcriptomic profiling to identify affected cellular pathways.

Main Results:

• PIC demonstrated potent and selective inhibition of T. gondii proliferation without harming host cells.
• PIC treatment led to disruption of mitochondrial integrity in T. gondii tachyzoites.
• Reduced mitochondrial membrane potential and ATP levels, coupled with increased ROS, were observed.
• Transcriptomic analysis revealed suppression of oxidative phosphorylation genes, confirming mitochondrial dysfunction.

Conclusions:

• Piceatannol effectively targets T. gondii by inducing mitochondrial impairment.
• PIC represents a promising therapeutic candidate for toxoplasmosis, acting via mitochondrial disruption.
• Further research into PIC's anti-parasitic effects warrants investigation for drug development.